Boryung

003850 · KOSPI · Health Care · SMALL CAP

Updated results.

Boryung updated its previously filed provisional (unaudited) consolidated results for Q4 2025: revenue of US$170M (−4.5% year on year), an operating loss of US$450K (from a profit a year earlier) and net income of US$14.6M (+59.37% year on year).

Earnings([Amended] Operating results (consolidated) (preliminary) (fair disclosure))· FILED 2026-02-13· RCEPT 20260213800021

US$170MRevenue
−4.5%Revenue vs a year earlier
−US$450KOperating profit

Converted at 1 USD ≈ ₩1,440.9 (filing-date rate, 2026-02-13 close)

What happened

Boryung updated its previously filed provisional (unaudited) consolidated results for Q4 2025: revenue of US$170M (−4.5% year on year), an operating loss of US$450K (from a profit a year earlier) and net income of US$14.6M (+59.37% year on year).

These are preliminary figures the company disclosed ahead of its audited report; the final numbers can differ.

RevenueUS$170M
Revenue vs a year earlier−4.5%
Operating profit−US$450K
Net incomeUS$14.6M
PeriodQ4 2025 (consolidated)
Filed2026-02-13, [Amended] Operating results (consolidated) (preliminary) (fair disclosure)
SourceDART rcept 20260213800021 → open original filing

Versions of this filing

  1. 2026-02-02Original
  2. 2026-02-13Amendment 1 (this page)

Source: DART. Information only, not investment advice.

For informational purposes only. This is not investment advice, a recommendation, or a solicitation to buy or sell any security. Do your own research; any investment decision is your own responsibility.

Data from DART, Korea's official corporate-filing system. Data sourced from official DART filings. Accuracy is not guaranteed. Figures are as of the date shown. As of 2026-02-13 (KST). · Converted at 1 USD ≈ ₩1,325 (rate of 2026-10-21).

Company summaries are generated and may contain errors; financial figures are mapped directly from official filings.